Genflow Bioscience

We have assembled a team of leading experts in the longevity and gene delivery fields

The Genflow Biosciences team also has decades of experience in the biotechnology and pharmaceutical sectors. Our team has worked with highly reputable institutions ranging from GSK, Pfizer and Schering Plough to world class universities such as Harvard, Oxford, LSE and UCL

Executive Team

Dr Eric Leire

Founder & CEO

Dr. Eric Leire brings to the Company a solid biotechnology expertise through his experience pharmaceutical industry experience (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of several private and public biotech companies such as APT Therapeutics, Paringenix), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).

He is the inventor of several medical patents. He also serves on the board of several biotechnology companies (Immunethep, BSIM, Inhatarget). Furthermore, Dr Eric has been CEO of several gene and cell therapy companies such as Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB:DDRT). He holds an MD from Grenoble University and an MBA from HEC, Paris and Kellogg, Northwestern University.

Bertrand Alexandre, MBA

COO

Bertrand Alexandre’s role is in advising the company in its corporate development strategy, providing input in its business plans and in developing future partnerships. Bertrand is an accomplished senior executive who worked for several years in Strategy Consulting at the Boston Consulting Group and has delivered exceptional business achievements at GSK and Celyad in Sales, Marketing and Business Development roles across therapeutic areas.

He graduated from Ecole Supérieure des Sciences Economiques et Commerciales (ESSEC) and holds an MBA from Kellogg School of Management, Northwestern University. With a background in both Consulting and Pharmaceutical / Biotechnology, he will help elevate Genflow to the next level.

Board of Directors

Dr Yassine Bendiabdallah

Non-Executive Director

Dr Yassine Bendiabdallah (MPharm, PhD, IP) is a Functional Medicine Healthy Ageing Specialist and an expert in Bio-identical Hormone therapy (BHRT). His previous academic degree as an anti-cancer drug discovery scientist with Cancer Research UK at University College London has earned him various distinctions and publications in peer-reviewed academic journals.

After a few years in academia, he embarked on an entrepreneurial journey and co-founded Zen Healthcare group of pharmacies and wellness clinics with multiple sites in London and worldwide partnerships. His current role as a clinical director and clinician with interests include age reversal therapies, functional approaches to medicine and intravenous micronutrient therapies. He also co-founded Pasithea Therapeutics, an innovative mental health group of clinics and Biotech and is currently Chief Operations Officer and head of UK Clinics. He is a director and board member of a number of companies within the healthcare industry.

Dr Eric Leire

Chief Executive Officer

Dr. Eric Leire, MD, MBA, Chief Executive Officer: brings to the Company a solid biotechnology expertise through his experience in the pharmaceutical industry (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of several private and public biotech companies such as APT Therapeutics, Paringenix), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).   He is the inventor of several patents.

He also serves on the board of several biotechnology companies such as Pherecydes (ALPH.PA), Inhatarget, Immunethep, BSIM Therapeutics.  Furthermore, Eric has been CEO of several Cell & gene therapy companies such as Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB: DDRT).  He has  also served as Non-Executive Director on the board of several cell & gene therapy companies such as Genizon (Canada) or FIT Biotechnology (Finland).  He holds an MD from Grenoble University and an MBA from HEC, Paris and Kellogg, Northwestern University.

Professor Andrew Scott

Non-Executive Director

Professor Andrew J Scott is Professor of Economics and a Research Fellow at the Centre for Economic Policy Research. Andrew previously held positions at Oxford University, London School of Economics and Harvard University. His MA is from Oxford, his M.Sc. from the London School of Economics and his D.Phil from Oxford University.

His research focuses on longevity, an ageing society, and fiscal policy and debt management and has been published widely in leading journals. His book, “The 100-Year Life” has been published in 15 languages and was runner up in both the FT/McKinsey and Japanese Business Book of the Year Awards. He was Managing Editor for the Royal Economic Society’s Economic Journal and Non-Executive Director for the UK’s Financial Services Authority. He is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office Honours Committee (Science and Technology), co-founder of The Longevity Forum and the World Economic Forum’s council on Healthy Ageing and Longevity.

Dr Peter King-Lewis

Non-Executive Director

Dr Peter King-Lewis studied Medicine at St Bartholomew’s Hospital in London. Prior to that he served for ten years as a Submarine Seaman Officer and Diver in The Royal Navy. Having completed Post Graduate Training in General Practice (St Bartholomew’s, St Thomas’, The Chelsea and Westminster and The Priory Roehampton) he founded a Private General Practice in Central London.

Continuing his interest in Hyperbaric Medicine he was an HSE Approved Medical Examiner of Divers. He has a strong interest in Bioidentical Hormones and has practiced Acupuncture alongside more conventional medicine. Dr King-Lewis also started and runs OfficeGP Ltd which provides Primary Care in the workplace for a variety of companies. During the last twenty-seven years he has also been the President of The Independent Doctors Federation and Hon Sec, President and Trustee of the Chelsea Clinical Society.

Professor Andrew Scott

Non-Executive Director

Professor Andrew J Scott is Professor of Economics and a Research Fellow at the Centre for Economic Policy Research. Andrew previously held positions at Oxford University, London School of Economics and Harvard University. His MA is from Oxford, his M.Sc. from the London School of Economics and his D.Phil from Oxford University.

His research focuses on longevity, an ageing society, and fiscal policy and debt management and has been published widely in leading journals. His book, “The 100-Year Life” has been published in 15 languages and was runner up in both the FT/McKinsey and Japanese Business Book of the Year Awards. He was Managing Editor for the Royal Economic Society’s Economic Journal and Non-Executive Director for the UK’s Financial Services Authority. He is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office Honours Committee (Science and Technology), co-founder of The Longevity Forum and the World Economic Forum’s council on Healthy Ageing and Longevity.

Dr Yassine Bendiabdallah

Non-Executive Director

Dr Yassine Bendiabdallah (MPharm, PhD, IP) is a Functional Medicine Healthy Ageing Specialist and an expert in Bio-identical Hormone therapy (BHRT). His previous academic degree as an anti-cancer drug discovery scientist with Cancer Research UK at University College London has earned him various distinctions and publications in peer-reviewed academic journals.

After a few years in academia, he embarked on an entrepreneurial journey and co-founded Zen Healthcare group of pharmacies and wellness clinics with multiple sites in London and worldwide partnerships. His current role as a clinical director and clinician with interests include age reversal therapies, functional approaches to medicine and intravenous micronutrient therapies. He also co-founded Pasithea Therapeutics, an innovative mental health group of clinics and Biotech and is currently Chief Operations Officer and head of UK Clinics. He is a director and board member of a number of companies within the healthcare industry.

Dr Peter King Lewis

Non-Executive Director

Dr Peter King-Lewis studied Medicine at St Bartholomew’s Hospital in London. Prior to that he served for ten years as a Submarine Seaman Officer and Diver in The Royal Navy. Having completed Post Graduate Training in General Practice (St Bartholomew’s, St Thomas’, The Chelsea and Westminster and The Priory Roehampton) he founded a Private General Practice in Central London.

Continuing his interest in Hyperbaric Medicine he was an HSE Approved Medical Examiner of Divers. He has a strong interest in Bioidentical Hormones and has practiced Acupuncture alongside more conventional medicine. Dr King-Lewis also started and runs OfficeGP Ltd which provides Primary Care in the workplace for a variety of companies. During the last twenty-seven years he has also been the President of The Independent Doctors Federation and Hon Sec, President and Trustee of the Chelsea Clinical Society.

Dr Eric Leire

Chief Executive Officer

Dr. Eric Leire, MD, MBA, Chief Executive Officer: brings to the Company a solid biotechnology expertise through his experience in the pharmaceutical industry (Pfizer, Schering Plough, Pharmacia), biotechnology (CEO of several private and public biotech companies such as APT Therapeutics, Paringenix), academia (Research Associate at the Harvard AIDS Institute) and Private Equity (partner at Biofund Venture Capital).   He is the inventor of several patents.

He also serves on the board of several biotechnology companies such as Pherecydes (ALPH.PA), Inhatarget, Immunethep, BSIM Therapeutics.  Furthermore, Eric has been CEO of several Cell & gene therapy companies such as Enochian Biosciences (Nasdaq: ENOB) and DanDrit Biotechnologies (OTC.QB: DDRT).  He has  also served as Non-Executive Director on the board of several cell & gene therapy companies such as Genizon (Canada) or FIT Biotechnology (Finland).  He holds an MD from Grenoble University and an MBA from HEC, Paris and Kellogg, Northwestern University.

Scientific Advisory Board

Genflow has established what the Directors believe is a strong scientific advisory board (“Scientific Advisory Board”) which is experienced in the field of longevity.

The role of the Scientific Advisory Board is first, to provide the Company with specific guidance on its research & development programs.  Furthermore, the Company can benefit from constant external perspectives which the members of the Scientific Advisory Board can bring to steer its research & development strategies.

Details of the Scientific Advisory Board Members are as follows:

Dr Eric Verdin

Eric Verdin, M.D. has been Chief Executive Officer and President of Buck Institute For Age Research since November 18, 2016. Dr. Verdin served as an Associate Director and Senior Investigator at the Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of California.

Dr. Verdin’s laboratory’s work focus on the role of protein acetylation in biological processes, particularly in modulating the immune response. Specifically, his laboratory studies histone deacetylase enzymes (HDACs) that remove acetyl groups from histones and non-histone proteins.

Dr Vera Gorbunova

Vera Gorbunova, PhD Co-director of the Rochester Ageing Research Center, University of Rochester New York. Dr Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Ageing Research Center.

Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Her work received awards from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Ageing Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.

Dr Matthew Hirschey

Matthew Hirschey, PhD is an Assistant Professor in the Departments of Medicine (Division of Endocrinology, Metabolism and Nutrition) and Pharmacology & Cancer Biology at Duke University Medical Center and a faculty member of the Sarah W. Stedman Nutrition and Metabolism Center and the newly formed Duke Molecular Physiology Institute. 

His research focuses on mitochondrial metabolism, with a particular interest in how cells use metabolites and chemical modifications to sense metabolism. He and his lab study the regulation of this process by a family of enzymes called sirtuins, and how sirtuins maintain energy homeostasis. His work has appeared in several leading journals, including Nature, Science, Cell Metabolism and Molecular Cell. He has received several awards including an Innovator Award from the American Heart Association, a New Scholar in Ageing Award from the Ellison Medical Foundation, and the Helmholtz Young Investigator in Diabetes (HeIDi) Award. His work is supported by grants from the American Heart Association, the Mallinckrodt Foundation, Friedreich’s Ataxia Research Alliance, the Ellison Medical Foundation, and the National Institutes of Health

Dr Manlio Vinciguerra

Manlio Vinciguerra, PhD is a Principal Investigator at the International Clinical Research Center (ICRC), Brno, Czech Republic. Previously he held a position of Senior Lecturer at the Institute for Liver and Digestive Health at the University College London (UCL), London, United Kingdom.

He received his PhD in Internal Medicine (2004) and research training at the University of Geneva, Switzerland, and at the European Molecular Biology Laboratory (EMBL), in Italy and in Germany (2005-2011). He obtained a degree in Biomolecular Sciences from the University of Catania, Italy, in 1999.  Dr. Vinciguerra unravelled important cellular signalling and epigenetics mechanisms involved in metabolic and infectious processes, stress and ageing in the heart and in the liver, such as PI3K/AKT/mTOR pathway and sirtuins, using a systems biology approach in cells and rodent models. He is a member of Who’s Who in Gerontology.

Dr Aubrey de Grey

Aubrey de Grey, PhD is an English author and biomedical gerontologist. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc. He is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Ageing (1999) and co-author of Ending Ageing (2007).

He is known for his view that medical technology may enable human beings alive today not to die from age-related causes. He is also an amateur mathematician who has contributed to the study of the Hadwiger–Nelson problem.  De Grey is an international adjunct professor of the Moscow Institute of Physics and Technology, a fellow of the Gerontological Society of America, the American Ageing Association, and the Institute for Ethics and Emerging Technologies. He has been interviewed in recent years in a number of news sources, including CBS 60 Minutes, the BBCThe New York TimesFortune MagazineThe Washington PostTEDPopular ScienceThe Colbert ReportTime, the Skeptics’ Guide to the Universe, and The Joe Rogan Experience. He is also a member of Flooved advisory board.

Dr Eric Verdin

Eric Verdin, M.D. has been Chief Executive Officer and President of Buck Institute For Age Research since November 18, 2016. Dr. Verdin served as an Associate Director and Senior Investigator at the Gladstone Institute of Virology and Immunology and a Professor of Medicine at the University of California.

Dr. Verdin’s laboratory’s work focus on the role of protein acetylation in biological processes, particularly in modulating the immune response. Specifically, his laboratory studies histone deacetylase enzymes (HDACs) that remove acetyl groups from histones and non-histone proteins.

Dr Vera Gorbunova

Vera Gorbunova, PhD Co-director of the Rochester Ageing Research Center, University of Rochester New York. Dr Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Ageing Research Center.

Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Her work received awards from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Ageing Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, the prize for research on ageing from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.

Dr Matthew Hirschey

Matthew Hirschey, PhD is an Assistant Professor in the Departments of Medicine (Division of Endocrinology, Metabolism and Nutrition) and Pharmacology & Cancer Biology at Duke University Medical Center and a faculty member of the Sarah W. Stedman Nutrition and Metabolism Center and the newly formed Duke Molecular Physiology Institute. 

His research focuses on mitochondrial metabolism, with a particular interest in how cells use metabolites and chemical modifications to sense metabolism. He and his lab study the regulation of this process by a family of enzymes called sirtuins, and how sirtuins maintain energy homeostasis. His work has appeared in several leading journals, including Nature, Science, Cell Metabolism and Molecular Cell. He has received several awards including an Innovator Award from the American Heart Association, a New Scholar in Ageing Award from the Ellison Medical Foundation, and the Helmholtz Young Investigator in Diabetes (HeIDi) Award. His work is supported by grants from the American Heart Association, the Mallinckrodt Foundation, Friedreich’s Ataxia Research Alliance, the Ellison Medical Foundation, and the National Institutes of Health

Dr Manlio Vinciguerra

Manlio Vinciguerra, PhD is a Principal Investigator at the International Clinical Research Center (ICRC), Brno, Czech Republic. Previously he held a position of Senior Lecturer at the Institute for Liver and Digestive Health at the University College London (UCL), London, United Kingdom.

He received his PhD in Internal Medicine (2004) and research training at the University of Geneva, Switzerland, and at the European Molecular Biology Laboratory (EMBL), in Italy and in Germany (2005-2011). He obtained a degree in Biomolecular Sciences from the University of Catania, Italy, in 1999.  Dr. Vinciguerra unravelled important cellular signalling and epigenetics mechanisms involved in metabolic and infectious processes, stress and ageing in the heart and in the liver, such as PI3K/AKT/mTOR pathway and sirtuins, using a systems biology approach in cells and rodent models. He is a member of Who’s Who in Gerontology.

Dr Aubrey de Grey

Aubrey de Grey, PhD is an English author and biomedical gerontologist. He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc. He is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Ageing (1999) and co-author of Ending Ageing (2007).

He is known for his view that medical technology may enable human beings alive today not to die from age-related causes. He is also an amateur mathematician who has contributed to the study of the Hadwiger–Nelson problem.  De Grey is an international adjunct professor of the Moscow Institute of Physics and Technology, a fellow of the Gerontological Society of America, the American Ageing Association, and the Institute for Ethics and Emerging Technologies. He has been interviewed in recent years in a number of news sources, including CBS 60 Minutes, the BBCThe New York TimesFortune MagazineThe Washington PostTEDPopular ScienceThe Colbert ReportTime, the Skeptics’ Guide to the Universe, and The Joe Rogan Experience. He is also a member of Flooved advisory board.